Press Release - September 17, 2014
Heidelberg, Germany, September 17, 2014 – Affimed Therapeutics today announced the closing of its initial public offering of 8,000,000 common shares at an initial public offering price of $7.00 per common share. In addition, Affimed has granted the underwriters a 30-day option to purchase up to an additional 1,200,000 common shares from Affimed at the public offering price, less underwriting discounts. Affimed’s common shares are listed on the NASDAQ Global Market under the symbol "AFMD."
Jefferies LLC, Leerink Partners LLC and BMO Capital Markets Corp. acted as joint book-running managers for the offering. Trout Capital LLC acted as co-manager.
A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on September 11, 2014. The offering was made only by means of a prospectus, copies of which may be obtained from Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, Telephone: (877) 547-6340, Email: Prospectus_Department@Jefferies.com; Leerink Partners LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, Telephone: (800) 808-7525, ext. 6142, Email: email@example.com; or BMO Capital Markets Corp., Attention: Equity Syndicate Department, 3 Times Square, New York, NY 10036, Telephone: (800) 414-3627, Email: firstname.lastname@example.org.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
Affimed is a clinical-stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies. Affimed’s product candidates are being developed in the field of immuno-oncology, which represents an innovative approach to cancer treatment that seeks to harness the body’s own immune defenses to fight tumor cells. The most potent cells of the human defense arsenal are types of white blood cells called Natural Killer cells, or NK-cells, and T-cells. Affimed’s proprietary, next-generation bispecific antibodies, called TandAbs for their tandem antibody structure, are designed to direct and establish a bridge between either NK-cells or T-cells and cancer cells, triggering a signal cascade that leads to the destruction of cancer cells.
Adi Hoess, CEO
Phone: +49 6221 65307-0